Baidu
map

Euro Radio:微波消融在治疗原发性甲状旁腺功能亢进中的价值

2022-08-20 shaosai MedSci原创

目前的治疗指南推荐甲状旁腺切除术(PTX)作为PHPT患者的标准治疗方法。

统计原发性甲状旁腺功能亢进症(pHPT)是第三大最常见的内分泌疾病,是矿物质代谢紊乱导致的相关综合症。据估计,全球每年甲状旁腺功能亢进症的发病率为每1000人中有1至4例,并有明显的性别倾向(女:男=3-4:1)。异常升高的甲状旁腺激素(PTH)和高钙血症可能引起一系列临床症状,如骨质疏松、骨折、肾结石、肾功能减退、神经认知功能受损,甚至出现高钙血症危象。近年来,随着社会经济生活条件的改善,越来越多的人开始重视常规体检,因此,无症状PHPT的检出率也随之提高。据观察,20-30%的无症状PHPT可发展为有症状的PHPT。

目前的治疗指南推荐甲状旁腺切除术(PTX)作为PHPT患者的标准治疗方法。近几十年来,已经有一些关于pHPT微创治疗的报道,如乙醇消融、激光消融、射频消融和高强度聚焦超声。作为热消融技术中最新的、令人振奋的进展之一,微波消融(MWA)已被常规应用于pHPT治疗。大多数研究表明,MWA可以有效地灭活pHPT结节,使血清PTH、钙和磷恢复正常。然而,受限于样本量小和随访时间短,治疗效果的确切证据并不详实。

近日,发表在European Radiology杂志的一项研究使用更大的样本量、更长的随访时间进一步对MWA和PTX进行了比较研究,分析了复发和顽固性PHPT的可能风险因素以获得关于MWA治疗PHPT的更明确的结果,并获得了更多预防手术失败的技术细节。

项回顾性研究在2015年1月至2020年10月期间招募了212名由MWA(MWA组)或PTX(PTX组)治疗的pHPT患者。基线数据通过倾向性评分匹配得到平衡。通过Kaplan-Meier方法评估临床治愈情况,并在MWA组和PTX组之间进行比较。采用Cox比例危害回归模型筛选出与持续或复发PHPT有关的风险因素。 

经过倾向性评分匹配,共有174名患者被纳入本研究,每组有87名患者。在随访期间(中位数,28.5个月),两组在临床治愈率(危险比,1.71;95%置信区间:0.81-3.62;P = .155)、PHPT持续率(13.8% vs. 10.3%,P = .643)、PHPT复发率(6.9% vs. 3.4%,P = .496)或主要并发症(6.9% vs. 3.4%,P = .496)方面没有差异。MWA的手术时间较短(30分钟对60分钟)、切口长度较小(0.1厘米对7厘米)、费用略高(25745元人民币对24111元人民币)(所有P < .001)。术前完整的甲状旁腺激素水平高(p = .01)和多个pHPT结节(p < .001)是两组中复发和持续pHPT的独立风险因素。 


 图片显示pHPT结节的MWA手术。a MIBI上pHPT结节有放射性浓(白色箭头)。b 超声显示甲状腺右低回声pHPT结节(白色箭头)。e 消融过程:在pHPT结节内部出现(白色箭头)周围的高回声区(白色箭头)。f CEUS显示覆盖pHPT结节的非增强区(白色箭头)。g MWA后一天消融区(2.0cm × 0.9cm)。h MWA后九个月,消融区被吸收

本研究表明,MWA和PTX在治疗pHPT的疗效和并发症方面是相当的。MWA是一项微创手术,且手术时间较短。本研究同时发现,多发性结节和高水平的血清iPTH是复发和持续的pHPT的风险因素。

原文出处:

Ying Wei,Zhen-Long Zhao,Xiao-Jing Cao,et al.Microwave ablation versus parathyroidectomy for the treatment of primary hyperparathyroidism: a cohort study.DOI:10.1007/s00330-022-08759-7

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1847060, encodeId=d2f7184e060ff, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sun Sep 11 01:44:25 CST 2022, time=2022-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379561, encodeId=877c13e956137, content=<a href='/topic/show?id=82e369829c0' target=_blank style='color:#2F92EE;'>#甲状旁腺功能亢进#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69829, encryptionId=82e369829c0, topicName=甲状旁腺功能亢进)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b796455, createdName=jmtang, createdTime=Sun Aug 21 08:44:25 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421909, encodeId=12e2142190961, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Sun Aug 21 08:44:25 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452504, encodeId=a3e01452504eb, content=<a href='/topic/show?id=d90469826e2' target=_blank style='color:#2F92EE;'>#甲状旁腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69826, encryptionId=d90469826e2, topicName=甲状旁腺)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84ba5566863, createdName=huperzia, createdTime=Sun Aug 21 08:44:25 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513941, encodeId=3cc015139410a, content=<a href='/topic/show?id=32d33e069ee' target=_blank style='color:#2F92EE;'>#原发性甲状旁腺功能亢进#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37069, encryptionId=32d33e069ee, topicName=原发性甲状旁腺功能亢进)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d7e10601864, createdName=12498877m101暂无昵称, createdTime=Sun Aug 21 08:44:25 CST 2022, time=2022-08-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1847060, encodeId=d2f7184e060ff, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sun Sep 11 01:44:25 CST 2022, time=2022-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379561, encodeId=877c13e956137, content=<a href='/topic/show?id=82e369829c0' target=_blank style='color:#2F92EE;'>#甲状旁腺功能亢进#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69829, encryptionId=82e369829c0, topicName=甲状旁腺功能亢进)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b796455, createdName=jmtang, createdTime=Sun Aug 21 08:44:25 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421909, encodeId=12e2142190961, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Sun Aug 21 08:44:25 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452504, encodeId=a3e01452504eb, content=<a href='/topic/show?id=d90469826e2' target=_blank style='color:#2F92EE;'>#甲状旁腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69826, encryptionId=d90469826e2, topicName=甲状旁腺)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84ba5566863, createdName=huperzia, createdTime=Sun Aug 21 08:44:25 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513941, encodeId=3cc015139410a, content=<a href='/topic/show?id=32d33e069ee' target=_blank style='color:#2F92EE;'>#原发性甲状旁腺功能亢进#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37069, encryptionId=32d33e069ee, topicName=原发性甲状旁腺功能亢进)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d7e10601864, createdName=12498877m101暂无昵称, createdTime=Sun Aug 21 08:44:25 CST 2022, time=2022-08-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1847060, encodeId=d2f7184e060ff, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sun Sep 11 01:44:25 CST 2022, time=2022-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379561, encodeId=877c13e956137, content=<a href='/topic/show?id=82e369829c0' target=_blank style='color:#2F92EE;'>#甲状旁腺功能亢进#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69829, encryptionId=82e369829c0, topicName=甲状旁腺功能亢进)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b796455, createdName=jmtang, createdTime=Sun Aug 21 08:44:25 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421909, encodeId=12e2142190961, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Sun Aug 21 08:44:25 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452504, encodeId=a3e01452504eb, content=<a href='/topic/show?id=d90469826e2' target=_blank style='color:#2F92EE;'>#甲状旁腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69826, encryptionId=d90469826e2, topicName=甲状旁腺)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84ba5566863, createdName=huperzia, createdTime=Sun Aug 21 08:44:25 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513941, encodeId=3cc015139410a, content=<a href='/topic/show?id=32d33e069ee' target=_blank style='color:#2F92EE;'>#原发性甲状旁腺功能亢进#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37069, encryptionId=32d33e069ee, topicName=原发性甲状旁腺功能亢进)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d7e10601864, createdName=12498877m101暂无昵称, createdTime=Sun Aug 21 08:44:25 CST 2022, time=2022-08-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1847060, encodeId=d2f7184e060ff, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sun Sep 11 01:44:25 CST 2022, time=2022-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379561, encodeId=877c13e956137, content=<a href='/topic/show?id=82e369829c0' target=_blank style='color:#2F92EE;'>#甲状旁腺功能亢进#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69829, encryptionId=82e369829c0, topicName=甲状旁腺功能亢进)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b796455, createdName=jmtang, createdTime=Sun Aug 21 08:44:25 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421909, encodeId=12e2142190961, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Sun Aug 21 08:44:25 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452504, encodeId=a3e01452504eb, content=<a href='/topic/show?id=d90469826e2' target=_blank style='color:#2F92EE;'>#甲状旁腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69826, encryptionId=d90469826e2, topicName=甲状旁腺)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84ba5566863, createdName=huperzia, createdTime=Sun Aug 21 08:44:25 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513941, encodeId=3cc015139410a, content=<a href='/topic/show?id=32d33e069ee' target=_blank style='color:#2F92EE;'>#原发性甲状旁腺功能亢进#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37069, encryptionId=32d33e069ee, topicName=原发性甲状旁腺功能亢进)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d7e10601864, createdName=12498877m101暂无昵称, createdTime=Sun Aug 21 08:44:25 CST 2022, time=2022-08-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1847060, encodeId=d2f7184e060ff, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Sun Sep 11 01:44:25 CST 2022, time=2022-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379561, encodeId=877c13e956137, content=<a href='/topic/show?id=82e369829c0' target=_blank style='color:#2F92EE;'>#甲状旁腺功能亢进#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69829, encryptionId=82e369829c0, topicName=甲状旁腺功能亢进)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b796455, createdName=jmtang, createdTime=Sun Aug 21 08:44:25 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421909, encodeId=12e2142190961, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Sun Aug 21 08:44:25 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452504, encodeId=a3e01452504eb, content=<a href='/topic/show?id=d90469826e2' target=_blank style='color:#2F92EE;'>#甲状旁腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69826, encryptionId=d90469826e2, topicName=甲状旁腺)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84ba5566863, createdName=huperzia, createdTime=Sun Aug 21 08:44:25 CST 2022, time=2022-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513941, encodeId=3cc015139410a, content=<a href='/topic/show?id=32d33e069ee' target=_blank style='color:#2F92EE;'>#原发性甲状旁腺功能亢进#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37069, encryptionId=32d33e069ee, topicName=原发性甲状旁腺功能亢进)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d7e10601864, createdName=12498877m101暂无昵称, createdTime=Sun Aug 21 08:44:25 CST 2022, time=2022-08-21, status=1, ipAttribution=)]

相关资讯

肺癌微波消融治疗经验分享

在世界范围内,肺癌的发病率和死亡率居癌症之首,全球每年发病约250万例,每年有超过160万人死于肺癌。

Brit J Cancer:微波消融治疗非小细胞肺癌患者根治术后肺部寡复发的效果

对于接受根治性手术切除后肺部寡复发的NSCLC患者,MWA应被认为是一种有效且安全的治疗手段。

European Radiology:微波消融与射频消融在包膜下HCC中的应用

热消融术是一种创伤较小的手术,可以作为肝癌患者的替代治疗方案来推荐。

Radiology:对于甲状腺乳头状癌患者,这一技术一定要知道!

微波消融(MWA)和射频消融(RFA)作为甲状腺乳头状癌(PTC)的微创治疗方式近年来备受关注。然而,T1N0M0 PTC的消融结果并不是很明确。

European Radiology:微波消融,为无法手术的I期非小细胞肺癌患者带来希望!

热消融主要包括射频消融(RFA)、微波消融(MWA)、冷冻消融和不可逆电穿孔。

Baidu
map
Baidu
map
Baidu
map